Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
126 hedge funds and large institutions have $818M invested in Day One Biopharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 40 increasing their positions, 27 reducing their positions, and 17 closing their positions.
242% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $394K
100% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 17
48% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 27
16% more funds holding
Funds holding: 109 → 126 (+17)
1.34% more ownership
Funds ownership: 81.84% → 83.18% (+1.3%)
36% less capital invested
Capital invested by funds: $1.29B → $818M (-$468M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$37.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$18.2M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$16M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$11M |
| 5 |
Goldman Sachs
New York
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$50M |
| 2 |
PCM
Pathway Capital Management
Irvine,
California
|
-$21.4M |
| 3 |
DM
Deerfield Management
New York
|
-$20.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.93M |
DAWN Hedge Fund Activity: Q1 2023 in Review
126 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q1 2023, worth a combined $818M — down 36% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new DAWN positions and 17 closed out — a net gain of 17 holders — while 40 added to existing stakes and 27 trimmed.
The largest buyer was Braidwell, adding an estimated $37.4M. The largest seller was Adage Capital Partners, cutting an estimated $50M.
- 126 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q1 2023, up from 109 in Q4 2022.
- Funds reported $818M of Day One Biopharmaceuticals stock for Q1 2023, down 36% quarter-over-quarter.
- 34 funds opened new Day One Biopharmaceuticals positions in Q1 2023 and 17 closed out, a net change of +17 holders.
- The largest Day One Biopharmaceuticals buyer in Q1 2023 was Braidwell, an estimated $37.4M added.
- The largest Day One Biopharmaceuticals seller in Q1 2023 was Adage Capital Partners, an estimated $50M sold.
Based on aggregated 13F filings for Q1 2023.